Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia

There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients. CD33 antigen is expressed on approximately 90% of myeloblasts, and gemtuzumab ozogamicin, as a monoclonal antibody directed against the CD33 surface antigen, may be a good target for these patients. H...

Full description

Saved in:
Bibliographic Details
Main Authors: Sule Unal, Meltem Cakir, Bariş Kuşkonmaz, Mualla Cetin, A Murat Tuncer
Format: Article
Language:English
Published: Hacettepe University Institute of Child Health 2009-02-01
Series:The Turkish Journal of Pediatrics
Online Access:https://turkjpediatr.org/article/view/2260
Tags: Add Tag
No Tags, Be the first to tag this record!